FTD leads to changes in personality and behavior. Understanding its genetic and molecular causes could lead to new ways to treat neurodegenerative diseases.
Love and intimacy are valuable for wellbeing at every age. But for older people, especially those in aged care, intimacy can be complicated. Carol Lefevre explores, through real life and fiction.
Although autosomal dominant Alzheimer’s disease is very rare, studying it provides researchers with valuable information on how the disease progresses in general.
Andrew Bubak, University of Colorado Anschutz Medical Campus; Diego Restrepo, University of Colorado Anschutz Medical Campus, and Maria Nagel, University of Colorado Anschutz Medical Campus
Inflammation and damage to the olfactory system from shingles, COVID-19 and herpes infections may contribute to Alzheimer’s disease.
In clinical trials, lecanemab slowed disease progression by 27% and reduced the amount of plaque found in the brains of those with Alzheimer’s disease.
An 18-month treatment with lecanemab slows functional and cognitive loss by 27 per cent in people with mild Alzheimer’s disease. But this is only the first step towards a real cure.
Impaired insulin receptors in the blood vessels between the blood and the brain may contribute to the insulin resistance observed in Alzheimer’s disease.
Two new dementia drugs are being hailed as breakthroughs. But what might be an incremental breakthrough for researchers, doesn’t mean a cure for patients.
Microglia, immune cells disguised as brain cells, are known as the janitors of the brain. Dialing up their usual duties just enough could provide an avenue to treat neurodegenerative disease.
The world’s longest running cohort study reveals risk factors for dementia. Families of athletes with early-onset dementia tell their stories. Could viruses cause Alzheimer’s? Listen to the Uncharted Brain: Decoding Dementia podcast series.